Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB3 in Acute STEMI Patients Undergoing PCI
NCT01539590Phase 2Terminated
- Sponsor
- Angion Biomedica Corp.
- Start
- Jul 2012
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of terevalefim in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Angion Biomedica Corp. Primary endpoints: Evaluation of Reduction in Infarct Size at 6 months and Evaluation of the Degree of Late Ventricular Remodeling at 6 months. Started Jul 2012; status: terminated.
02
Drugs
terevalefim
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01539590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01539590.